** Shares of drug developer Relmada Therapeutics rise 4.9% to 48 cents
** Co says it has commenced a process to explore strategic alternatives after discontinuing two late-stage studies planned for the development of its depression drug
** Co plans to consider a wide range of options including sale of company assets, a sale of the company, a merger or a reverse merger; adds it has not set a timetable for completion of the evaluation process
** Says co is in the process of engaging a financial advisor to assist in the strategic review process
** The stock fell more than 70% last week after the company said its depression drug, esmethadone, was "unlikely" to meet the main goal of a late-stage trial
** Including session moves, stock down 88.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。